Startups
Avectas is a cell engineering business focused on improving the cost, manufacturing and patient outcomes for the next generation of cellular therapies. Avectas is developing a unique delivery technology platform, Solupore®, to enable the ex-vivo manufacture of gene modified cell therapy products, with partners. Solupore® is a patented, non-viral, cell engineering technology that permeabilizes the target cell membrane and allows efficient transfer of cargo into cells whilst retaining very high levels of cell viability and functionality. The Solupore® technology is designed for use with mRNA, DNA, and proteins, including gene editing tools such as CRISPR. Solupore® achieves excellent engineering efficiencies for delivery of these payloads to primary T cells and NK cells for immuno-oncology and gene editing applications. Avectas is currently developing the clinical (cGMP) technology embodiment while enhancing its dataset, implementing its commercialization strategy and building out the team.
Overview
Location
Canada, Ontario, Toronto
Employees
11-50
Total raised
$30M
Founded date
2011
Funding Rounds 2
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Apr 11, 2019 | Funding round | $10M |
Mentions in press and media 4
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Apr 16, 2020 | Avectas Raises $20M in Series C Funding | Avectas, an Irish cell engineering technology company, has completed a significant new Series C equity funding of approximately $20m. The round, which brought the total equity invested in the business to date to $40m, was led by existing sh... |
| Apr 11, 2019 | Avectas nabs $10M backing | Avectas has received a $10 million investment in a round lead by Irish business angel Seamus Mulligan. The biotech startup focuses on cell engineering and will use the funds to scale operations. View details |
| Apr 9, 2019 | Avectas Raises $10M in Equity Funding | Avectas, a Dublin, Ireland- and Cambridge, MA-based cell engineering technology company, completed a US$10m equity financing. The round was led by Seamus Mulligan. The company intends to use the funds to accelerate the development, scale-up... |
Reviews 0
FAQ about Avectas
When was Avectas founded?
Avectas was founded in 2011.
How much funding has Avectas raised?
Avectas has raised $30M in total across 2 funding rounds.
What funding rounds has Avectas raised?
Parsers VC lists 2 funding rounds of Avectas, among them a funding round of $10M on Apr 11, 2019.
What has the press written about Avectas?
Parsers VC has collected 4 articles mentioning Avectas, among them “Avectas Raises $20M in Series C Funding” (Apr 16, 2020) and “Avectas nabs $10M backing” (Apr 11, 2019).
Is Avectas still active?
Yes, Avectas is active; its latest activity on Parsers VC dates from Apr 22, 2021.